OBJECTIVES

: To assess the Budget Impact for the Spanish National Healthcare System (NHS) of the use of once-daily umeclidinium bromide/vilanterol (UMEC/VI) 62.5/25 mcg compared with the currently prescribed LAMA/LABA combinations for Chronic Obstructive Pulmonary Disease (COPD) treatment.

METHODS

: An Excel-based model with one-year time-horizon was developed to estimate the economic impact, limited to pharmacological costs, of prescribing UMEC/VI as an alternative treatment to currently prescribed LAMA/LABA combinations. The total number of patients on LAMA/LABA treatment was estimated based on local epidemiological and prescription data. To estimate the total pharmacological cost for current use of LAMA/LABA, the weighted average pharmacological cost per patient/year was calculated based on current market shares of LAMA/LABA combinations, assuming 12-packs consumed per patient/year. Drug costs were taken from public sources at Price-to-Public plus Value-Added-Tax (€,2017). A series of hypothetical scenarios was established, increasing UMEC/VI market share (+20%, +40%, +60%, 100%) within the LAMA/LABA class. Budget impact was estimated as the difference in total pharmacological costs between hypothetical scenarios and current scenario.

RESULTS

: CONCLUSIONS

: The use of UMEC/VI versus other LAMA/LABA combinations has the potential to reduce the COPD pharmacologic budget that may help to reduce the economic burden of COPD.